{"nctId":"NCT01413204","briefTitle":"Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes","startDateStruct":{"date":"2011-07"},"conditions":["Type 2 Diabetes Mellitus"],"count":272,"armGroups":[{"label":"TA-7284 Low","type":"EXPERIMENTAL","interventionNames":["Drug: TA-7284 Low"]},{"label":"TA-7284 High","type":"EXPERIMENTAL","interventionNames":["Drug: TA-7284 High"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"TA-7284 Low","otherNames":[]},{"name":"TA-7284 High","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women age ≥20 years old\n* Diagnosed with Type 2 diabetes mellitus at least 3 months before run-in period\n* HbA1c of ≥7.0% and ≤10.0%\n\nExclusion Criteria:\n\n* Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus\n* Past or current history of severe diabetic complications\n* Fasting plasma glucose \\> 270 mg/dL before treatment start\n* History of hereditary glucose-galactose malabsorption or primary renal glucosuria\n* Patients requiring insulin therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"0.07"},{"groupId":"OG001","value":"-0.76","spread":"0.07"},{"groupId":"OG002","value":"0.29","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Body Weight","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Blood Pressure","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Postprandial Plasma Glucose, Insulin and Urinary Glucose Excretion After a 75 g Oral Glucose Tolerance Test","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events, Laboratory Tests, 12-lead ECG and Vital Signs","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":90},"commonTop":["Nasopharyngitis","Blood ketone body increased","Hypoglycaemia unawareness","Contusion","Pharyngitis"]}}}